Page last updated: 2024-11-12

ginsenoside rb1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
PanaxgenusAn araliaceous genus of plants that contains a number of pharmacologically active agents used as stimulants, sedatives, and tonics, especially in traditional medicine. Sometimes confused with Siberian ginseng (ELEUTHEROCOCCUS).[MeSH]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]
Panax japonicusspecies[no description available]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]
Panax ginsengspecies[no description available]AraliaceaeThe ginseng plant family of the order Apiales, subclass Rosidae, class Magnoliopsida. Leaves are generally alternate, large, and compound. Flowers are five-parted and arranged in compound flat-topped umbels. The fruit is a berry or (rarely) a drupe (a one-seeded fruit). It is well known for plant preparations used as adaptogens (immune support and anti-fatigue).[MeSH]

Cross-References

ID SourceID
PubMed CID9898279
CHEMBL ID501515
CHEBI ID67989
MeSH IDM0062220

Synonyms (63)

Synonym
BIDD:ER0108
nsc 310103
2-o-beta-glucopyranosyl-(3beta,12beta)-20-((6-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl-beta-d-glucopyranoside
LS-71528 ,
beta-d-glucopyranoside, (3-beta,12-beta)-20-((6-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-
notoginsenoside rb1
panaxoside rb1
sanchinoside rb1
ginsenoside-rb1
gs-rb1
nsc-310103
ginsenoside rb1 ,
pseudoginsenoside d
arasaponin e1
sanchinoside e1
einecs 255-532-8
gynosaponin c
gypenoside iii
panax saponin e
(20s)-ginsenoside rb1
3beta-[beta-d-glucopyranosyl-(1->2)-beta-d glucopyranosyloxy]-20-[beta-d-glucopyranosyl-(1->2)-beta-d glucopyranosyloxy]dammar-24-en-12beta-ol
panaxsaponin e
DB06749
chebi:67989 ,
CHEMBL501515 ,
bdbm50317541
20(s)-ginsenoside rb1
(3beta,12beta)-20-[(6-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy]-12-hydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-beta-d-glucopyranoside
(3beta,12beta)-20-{[6-o-(beta-d-glucopyranosyl)-beta-d-glucopyranosyl]oxy}-12-hydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-beta-d-glucopyranoside
gsrb1
S3924
7413s0wmh6 ,
unii-7413s0wmh6
AKOS025311537
CS-3829
ginsenosiderb1
C20713
Q-100470
ginsenoside rb1 (constituent of american ginseng, asian ginseng, and tienchi ginseng) [dsc]
.beta.-d-glucopyranoside, (3.beta.,12.beta.)-20-((6-o-.beta.-d-glucopyranosyl-.beta.-d-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-o-.beta.-d-glucopyranosyl-
ginsenoside rb1 [who-dd]
ginsenoside rb1 [usp-rs]
HY-N0039
2-o-beta-glucopyranosyl-(3beta,12beta)-20-[(6-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy]-12-hydroxydammar-24-en-3-yl beta-d-glucopyranoside
gypenoside cento
ginsenoside rb1, primary pharmaceutical reference standard
ginsenoside rb1, european pharmacopoeia (ep) reference standard
GZYPWOGIYAIIPV-JBDTYSNRSA-N
HMS3885O12
CCG-270640
NCGC00347398-04
ginsenoside rb1 - 94%
XG164977
BS-32417
EX-A6786
DTXSID401316929
beta-d-glucopyranoside, (3beta,12beta)-20-((6-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-
ginsenoside rb1 (constituent of american ginseng, asian ginseng, and tienchi ginseng)
3beta-(beta-d-glucopyranosyl-(1->2)-beta-d glucopyranosyloxy)-20-(beta-d-glucopyranosyl-(1->2)-beta-d glucopyranosyloxy)dammar-24-en-12beta-ol
ginsenoside rb1 (usp-rs)
(3beta,12beta)-20-((6-o-(beta-d-glucopyranosyl)-beta-d-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-beta-d-glucopyranoside
(3beta,12beta)-20-((6-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl 2-o-beta-d-glucopyranosyl-beta-d-glucopyranoside
13 - ginseng supplement chemical analysis

Research Excerpts

Overview

Ginsenoside Rb1 (GnRb1) is a natural compound obtained from the roots of Panax ginseng. It is known for its fat-reducing, anti-inflammatory effects and neuroprotective potential.

ExcerptReferenceRelevance
"Ginsenoside Rb1 (GnRb1) is a natural compound obtained from the roots of"( Ginsenoside Rb1 Mitigates
Abdelrahman, M; Chen, C; Gu, X; Hanif, S; Niu, K; Rajput, SA; Riaz, U; Safdar, M; Shaukat, A; Shaukat, I; Shaukat, S; Shukat, R; Sun, X; Yang, L; Yao, Z; Ye, T; Zhang, X; Zhao, J, 2021
)
2.79
"Ginsenoside Rb1is a major ginsenoside of Panax ginseng particularly known for its neuroprotective potential."( Ginsenoside Rb1 inhibits astrocyte activation and promotes transfer of astrocytic mitochondria to neurons against ischemic stroke.
Alolga, RN; Cai, YY; Huang, FQ; Li, J; Liu, B; Ni, XC; Wang, HF; Yang, D, 2022
)
2.89
"Ginsenoside Rb1 (Rb1) is a major active compound in Panax ginseng and has shown considerable anti-inflammation effects. "( Ginsenoside Rb1 from Panax ginseng attenuates monoiodoacetate-induced osteoarthritis by inhibiting miR-21-5p/FGF18-mediated inflammation.
Che, G; Luan, J; Man, G; Xiao, F, 2022
)
3.61
"Ginsenoside Rb1 (Rb1) is a biologically active component of ginseng ["( Ginsenoside Rb1 reduces oxidative/carbonyl stress damage and ameliorates inflammation in the lung of streptozotocin-induced diabetic rats.
Bai, Y; Chen, X; Deng, L; Feng, C; Liu, J; Ma, Z; Shi, J; Su, H; Tian, CJ; Wang, Y; Zhen, Z, 2022
)
3.61
"Ginsenoside Rb1 (Rb1) is a main active ingredient, which is known for its fat-reducing, anti-inflammatory effects."( Ginsenoside Rb1 Interfered with Macrophage Activation by Activating PPARγ to Inhibit Insulin Resistance in Obesity.
Ding, H; Dong, J; Huang, Q; Qiu, Z; Wang, Y; Xu, J; Yao, F, 2023
)
3.07
"Ginsenoside Rb1 is a major bioactive ingredient of ginseng, which shows very specific anti-apoptosis and anti-oxidant activities."( Ginsenoside Rb1 protects porcine oocytes against methylglyoxal damage thus it improves the quality of parthenogenetic activation and in vitro fertilization embryos.
Han, SZ; Kang, JD; Khan, N; Li, ZY; Luo, ZB; Quan, BH; Xuan, MF; Yin, XJ, 2021
)
2.79
"Ginsenoside Rb1 (GRb1) is a major active component of Panax, which is widely used to improve learning and memory."( Ginsenoside Rb1 protected PC12 cells from Aβ
Cai, J; Changhong, K; Peng, Y; Yuan, Z, 2021
)
2.79
"Ginsenoside Rb1 (Rb1) is an active ingredient of traditional Chinese medicine with cardioprotective effect."( Ginsenoside Rb1 ameliorates cardiotoxicity triggered by aconitine via inhibiting calcium overload and pyroptosis.
Sun, G; Sun, H; Sun, X; Wang, M; Wang, R, 2021
)
2.79
"Ginsenoside Rb1 (Rb1) is a principle active ingredient extracted from the root of"( Ginsenoside Rb1 Alleviates Lipopolysaccharide-Induced Inflammatory Injury by Downregulating miR-222 in WI-38 Cells.
Fang, X; Gao, D; Jia, P; Jin, P; Li, F; Li, M; Wang, H; Wei, E,
)
2.3
"Ginsenoside Rb1 is an important saponin of ginseng(s); however, Rb1, with 3-O- and 20-O-sugar moieties, has low bioavailability. "( Conversion of Ginsenoside Rb1 into Six Types of Highly Bioactive Ginsenoside Rg3 and Its Derivatives by FeCl
Jin, F; Li, G; Liu, C; Song, J; Wang, Y; Xu, L; Yang, J; Yu, H, 2018
)
2.28
"Ginsenoside Rb1 (GRb1) is an ethanol extract from ginseng and contains a highly concentrated form of ginsenoside."( Ginsenoside Rb1 does not halt osteoporotic bone loss in ovariectomized rats.
Bei, J; Cui, L; Hu, Z; Lin, S; Wu, J; Wu, T; Xu, B; Zhang, X; Zou, L, 2018
)
2.64
"Ginsenoside Rb1 (Rb1) is a major primary bioactive component extracted by Panax ginseng, which has numerous pharmacological functions such as anti-cancer, anti-inflammatory, and antioxidant."( Ginsenoside Rb1 ameliorates Staphylococcus aureus-induced Acute Lung Injury through attenuating NF-κB and MAPK activation.
Akhtar, M; Deng, G; Guo, S; Guo, YF; Hassan, M; Jiang, K; Rajput, SA; Shaukat, A; Shaukat, I; Umar, T; Wu, H; Yang, C; Yang, Y; Zahoor, A; Zhang, T; Zhao, G, 2019
)
2.68
"Ginsenoside Rb1 is an active component in ginseng. "( [Effect of ginsenoside Rb1 in ameliorating insulin resistance and ectopic fat deposition in obese mice induced by high fat diet].
Shang, WB; Wang, GQ; Yu, XZ; Zhao, J, 2013
)
2.22
"Ginsenoside Rb1 is a biologically active compound that is abundant in ginseng (Panax ginseng). "( Effects of broad-spectrum antibiotics on the metabolism and pharmacokinetics of ginsenoside Rb1: a study on rats׳ gut microflora influenced by lincomycin.
Fan, L; Li, X; Peng, Y; Wang, M; Xu, R, 2014
)
2.07
"Ginsenoside Rb1 is a potential therapeutic agent for the treatment of spinal cord ischemia‑reperfusion injury (SCII), although it has not yet been investigated in depth. "( Ginsenoside Rb1 inhibits neuronal apoptosis and damage, enhances spinal aquaporin 4 expression and improves neurological deficits in rats with spinal cord ischemia‑reperfusion injury.
Huang, F; Li, Y; Li, YN; Wu, YT; Yin, F; Zhang, YF; Zhao, DX; Zhu, QS, 2015
)
3.3
"Ginsenoside Rb1 (GS-Rb1) is a well-known antioxidant derived from traditionally used herbal medicine ginseng. "( Impact of extended ginsenoside Rb1 on early chronic kidney disease: a randomized, placebo-controlled study.
Li, Y; Lu, Q; Sun, J; Wu, J; Xu, X, 2017
)
2.23
"Ginsenoside Rb1 is a representative component of panaxadiol saponins, which belongs to dammarane-type tritepenoid saponins and mainly exists in family araliaceae. "( [Advance of pharmacological study on ginsenoside Rb1].
Jia, JM; Wang, ZQ; Wu, LJ; Wu, YL, 2008
)
2.06
"Ginsenoside Rb1 (GRb1) is a natural product extracted from Panax ginseng C.A."( Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia.
Jiang, Y; Liu, X; Lu, T; Wu, L; Xu, G; Zhu, J, 2012
)
1.33
"Ginsenoside Rb1 (GRb1) is a major ingredient of ginseng and has a wide range of neuroprotection effects. "( Inhibitory effects of ginsenoside Rb1 on neuroinflammation following systemic lipopolysaccharide treatment in mice.
Lee, JS; Shin, JW; Sohn, NW; Song, JH, 2013
)
2.15
"Ginsenoside Rb1 is an active protopanaxadiol saponin from Panax species. "( Comparative analysis on microbial and rat metabolism of ginsenoside Rb1 by high-performance liquid chromatography coupled with tandem mass spectrometry.
Chen, G; Guan, S; Guo, DA; Huang, H; Lu, Z; Song, Y; Wu, L; Yang, M; Zhang, J, 2008
)
2.03

Effects

Ginsenoside Rb1 (GRb1) has been determined to exert diverse neuromodulatory effects including antistress effects in the brain. The mechanisms remain unclear. GinsenosideRb1 has been shown to benefit many central nervous system (CNS) disorders, including stroke.

ExcerptReferenceRelevance
"Ginsenoside Rb1 has a boosting effect on the immune efficacy of the H1N1 influenza vaccine and is promising as a novel adjuvant to regulate the microecological balance and achieve an anti-infective effect."( Ginsenoside Rb1 enhanced immunity and altered the gut microflora in mice immunized by H1N1 influenza vaccine.
Fang, B; He, Y; Lu, R; Shen, G; Wan, C; Wu, H; Wu, X; Yang, Y; Zhu, C, 2023
)
3.8
"ginsenoside Rb1 (Gn-Rb1) has been verified to be cardioprotective in cardiac remodeling and cardiac ischemia/reperfusion (I/R) injury, but its role is less known in CA."( Ginsenoside Rb1 Improves Post-Cardiac Arrest Myocardial Stunning and Cerebral Outcomes by Regulating the Keap1/Nrf2 Pathway.
Chen, L; Chen, T; Geng, N; He, B; Huo, H; Jiang, L; Shao, Q; Xiao, Q; Zhang, H, 2023
)
3.07
"Ginsenoside Rb1 (Rb1) has been reported to protect the cardiovascular system against vascular diseases, yet its role in VC and the underlying mechanisms remain unclear."( Ginsenoside Rb1 ameliorates CKD-associated vascular calcification by inhibiting the Wnt/β-catenin pathway.
Dai, H; Dong, M; Guo, M; Guo, R; Ji, X; Lin, Z; Lu, H; Wang, L; Zhang, X; Zhang, Z; Zhou, P, 2019
)
2.68
"Ginsenoside Rb1 (gRb1) has been proved to protect human umbilical vein cells (HUVECs), but its effect on ox-LDL-induced endothelium senescence and the underlying mechanism remains unknown."( Ginsenoside Rb1 Alleviates Oxidative Low-Density Lipoprotein-Induced Vascular Endothelium Senescence via the SIRT1/Beclin-1/Autophagy Axis.
Hao, B; Liu, D; Liu, Y; Qian, X; Shi, G; Song, Z; Wang, M; Wu, C; Wu, L; Yu, S; Zhou, B; Zhu, J, 2020
)
2.72
"Ginsenoside Rb1 has been shown to have antidiabetic and anti-inflammatory effects. "( The ginsenoside metabolite compound K stimulates glucagon-like peptide-1 secretion in NCI-H716 cells by regulating the RhoA/ROCKs/YAP signaling pathway and cytoskeleton formation.
Feng, X; Huang, Q; Ni, H; Tian, F; Wang, X; Yuan, X, 2021
)
2.06
"Ginsenoside Rb1 (Rb1) has been reported for its antioxidant potential and medicinal properties."( Ginsenoside Rb1 prevents deoxynivalenol-induced immune injury via alleviating oxidative stress and apoptosis in mice.
Abdel-Daim, MM; Akhtar, RW; Alamoudi, MO; Aljarai, RM; Alotaibi, MA; El Askary, A; Iqbal, Z; Kamboh, AA; Mohammedsaleh, ZM; Rajput, IR; Rajput, SA; Raza, MA; Saeed, M; Shah, SAH; Shaukat, A, 2021
)
2.79
"Ginsenoside Rb1 (Rb1) has been reported to have the ability to attenuate I/R injury, but its effect on energy metabolism during cardiac I/R and the underlying mechanism remain unknown."( Ginsenoside Rb1 protects against ischemia/reperfusion-induced myocardial injury via energy metabolism regulation mediated by RhoA signaling pathway.
-Li, Q; Chang, X; Cui, YC; Fan, JY; Han, JY; Hu, BH; Li, L; Liu, YY; Pan, CS; Sun, K; Yan, L, 2017
)
2.62
"Ginsenoside Rb1 has been demonstrated to protect dopaminergic (DA) neurons from death in vitro. "( Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease.
Dou, CY; Huang, SQ; Kang, XP; Liu, Y; Peng, L; Wen, L; Zhang, YL; Zhuo, RG, 2018
)
3.37
"Ginsenoside Rb1 (Rb1) has been reported to have varieties of neuroprotective effects. "( Ginsenoside Rb1 Protects the Brain from Damage Induced by Epileptic Seizure via Nrf2/ARE Signaling.
Miao, W; Shi, Y; Teng, J; Zhang, L, 2018
)
3.37
"Ginsenoside Rb1 (GRb1) has been determined to exert diverse neuromodulatory effects including antistress effects in the brain. "( Effects of ginsenoside Rb1 on the stress-induced changes of BDNF and HSP70 expression in rat hippocampus.
Cho, KH; Kim, D; Kim, M; Kim, SO; Kim, SY; Lee, EH; Lee, M; Park, Y, 2014
)
2.23
"Ginsenoside Rb1 has been demonstrated with neuroprotective effects, but the mechanisms remain unclear. "( Neuroprotective effect of ginsenoside Rb1 on glutamate-induced neurotoxicity: with emphasis on autophagy.
Chen, M; Chen, Z; Jiang, Y; Liu, X; Lu, T; Ni, G; Wei, N; Xu, G; Yue, X, 2010
)
2.1
"Ginsenoside Rb1 (GRb1) has been shown to benefit many central nervous system (CNS) disorders, including stroke. "( Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats.
Chen, Z; Jiang, Y; Liu, X; Lu, T; Ma, M; Wei, N; Xu, G; Yue, X; Zhou, Z, 2011
)
2.2
"Ginsenoside Rb1 has been shown to confer cardioprotection against ischemia reperfusion injury."( Ginsenoside Rb1 preconditioning enhances eNOS expression and attenuates myocardial ischemia/reperfusion injury in diabetic rats.
Hou, JB; Wu, Y; Xia, R; Xia, ZY; Xu, JJ; Zhang, L; Zhao, B, 2011
)
2.53

Actions

Ginsenoside Rb1 can obviously inhibit renal interstitial fibrosis in rats with UUO. Its mechanism possibly via against the oxidative damage and suppressing TGF-beta1 expression.

ExcerptReferenceRelevance
"Ginsenoside Rb1 promotes burn wound healing."( Effects of ginsenoside Rb1 on hypertrophic scar remodeling in rabbit model.
Kang, EH; Lee, DW; Lee, MC; Lew, DH; Roh, H; Tark, KC, 2015
)
1.53
"Ginsenoside Rb1 can obviously inhibit renal interstitial fibrosis in rats with UUO, its mechanism possibly via against the oxidative damage and suppressing TGF-beta1 expression."( Ginsenoside Rb1, a panoxadiol saponin against oxidative damage and renal interstitial fibrosis in rats with unilateral ureteral obstruction.
Deng, Y; Fan, JM; Liu, HC; Xie, XS; Yang, M; Zuo, C, 2009
)
3.24

Treatment

Ginsenoside Rb1 (Rb1) chronic treatment improved central leptin sensitivity, leptin-JAK2-STAT3 signaling, and leptin-induced regulation of BDNF expression in the prefrontal cortex of high-fat diet-induced obese mice. Pretreatment could increase the plasma CORT and ACTH concentrations, maintain the mRNA expression of TrkB, thus relieving injury induced by acute immobilization stress.

ExcerptReferenceRelevance
"Ginsenoside Rb1 (Rb1) chronic treatment improved central leptin sensitivity, leptin-JAK2-STAT3 signaling, and leptin-induced regulation of BDNF expression in the prefrontal cortex of high-fat diet-induced obese mice. "( Ginsenoside Rb1 improves leptin sensitivity in the prefrontal cortex in obese mice.
Bell, C; Huang, XF; Wu, Y; Yu, Y, 2018
)
3.37
"Ginsenoside Rb1-treated rats had a smaller infarct volume than the positive control."( Preventive and therapeutic effects of ginsenoside Rb1 for neural injury during cerebral infarction in rats.
Jiang, Z; Leng, J; Lu, Y; Peng, T; Wang, Y; Xie, Q; Zhang, X, 2013
)
1.38
"Ginsenoside Rb1 treatment dramatically suppressed Ang II-induced diameter enlargement, extracellular matrix degradation, matrix metalloproteinase (MMP) production, inflammatory cell infiltration, and vascular smooth muscle cell (VSMC) dysfunction."( Ginsenoside Rb1 attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of the JNK and p38 signaling pathways.
He, C; Li, P; Su, H; Tian, K; Wan, JB; Zhang, XJ, 2015
)
2.58
"Treatment with ginsenoside Rb1 attenuated the diabetes-induced increase in the diameter of retinal blood vessels. "( Ginsenoside Rb1 attenuates diabetic retinopathy in streptozotocin-induced diabetic rats1.
Dong, C; Dong, M; Li, G; Li, Y; Liu, P; Wang, H, 2019
)
2.31
"Pretreatment by ginsenoside Rb1 could increase the plasma CORT and ACTH concentrations, maintain the mRNA expression of TrkB, thus relieving injury induced by acute immobilization stress."( [Effects of ginsenoside Rb1 on the mRNA expression of tyrosine kinase B in the hippocampus of acute immobilization stress rats].
Chen, BC; Jia, DY; Jin, W; Liu, JW; Wang, JL; Yao, YR; Zhang, MX, 2013
)
1.11
"Treatment with ginsenoside Rb1 attenuated the initial downregulation and advanced the recovery of AQP4 expression levels, suggesting a possible mechanism for the therapeutic effects on SCII."( Ginsenoside Rb1 inhibits neuronal apoptosis and damage, enhances spinal aquaporin 4 expression and improves neurological deficits in rats with spinal cord ischemia‑reperfusion injury.
Huang, F; Li, Y; Li, YN; Wu, YT; Yin, F; Zhang, YF; Zhao, DX; Zhu, QS, 2015
)
2.2
"Pretreatment with ginsenoside Rb1 significantly inhibited RANKL-induced the gene expression of c-Fos and nuclear factor of activated T-cells c1 (NFATc1), which are two essential and crucial transcription factors for osteoclast formation."( Ginsenoside Rb1 inhibits osteoclastogenesis by modulating NF-κB and MAPKs pathways.
Cheng, B; Du, J; Li, J; Ling, C; Lv, X; Weng, L, 2012
)
2.15
"Pretreatment with ginsenoside Rb1 reduced Abeta(25-35) -induced hyperphosphorylation of tau protein and decreased the lever of p25, but had no effect on cdk5."( [Ginsenoside Rb1 attenuates beta-amyloid peptide(25-35) -induced hyperphosphorylation of tau protein through CDK5 signal pathway].
Chen, XC; Fang, YX; Huang, TW; Lin, ZY; Pan, XD; Song, JQ; Xie, YH; Zhang, J, 2007
)
1.57

Toxicity

ExcerptReferenceRelevance
"niger as safe microorganism."( Biotransformation of Ginsenoside Rb1 to Ginsenoside CK by Strain XD101: a Safe Bioconversion Strategy.
Fan, D; Jiang, Y; Li, W, 2021
)
0.94

Pharmacokinetics

consumption of lincomycin could lead to the formation of specific metabolites and pharmacokinetic changes of ginsenoside Rb1 in the gut. These changes are attributed to alterations in metabolic activities of intestinal bacteria.

ExcerptReferenceRelevance
" The pharmacokinetic profiles of the main PNS are still not accurately investigated."( Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats.
Chen, DF; Fang, XL; Xu, QF, 2003
)
0.59
"Enzyme-linked immunosorbent assay (ELISA) systems using anti-ginsenoside Rb1 (G-Rb1) and Rg1 (G-Rg1) monoclonal antibodies (MAbs) were established for pharmacokinetic investigations of G-Rb1 and G-Rg1 in rat serum."( Pharmacokinetic study of ginsenosides Rb1 and Rg1 in rat by ELISA using anti-ginsenosides Rb1 and Rg1 monoclonal antibodies.
Chao, Z; Shoyama, Y; Tanaka, H, 2006
)
0.58
" The concentrations of Rb1, Rg1 and R1 were measured by high performance liquid chromatography (HPLC), and statistic program DAS was applied to the calculation of pharmacokinetic parameters."( [In vivo distribution and pharmacokinetics of multiple effective components contained in Panax notoginseng saponins after intratympanic administration].
Chen, G; Hou, S; Mu, L; Nan, H; Zhang, X, 2011
)
0.37
" However, the pharmacokinetic parameters showed significant differences between the three components."( [In vivo distribution and pharmacokinetics of multiple effective components contained in Panax notoginseng saponins after intratympanic administration].
Chen, G; Hou, S; Mu, L; Nan, H; Zhang, X, 2011
)
0.37
" The value of Rb(1) is higher than that of Rb(2) or Rb(3), indicating that ginsenosides with hexose and hydroxyl groups (Rb(1)) could present better pharmacokinetic behaviors than those with pentose groups in the same glycosylation site by oral administration."( Determination of ginsenosides Rb1, Rb2, and Rb3 in rat plasma by a rapid and sensitive liquid chromatography tandem mass spectrometry method: Application in a pharmacokinetic study.
Liu, M; Liu, Z; Su, C; Su, W; Tang, L; Yang, C; Zhao, J, 2012
)
0.38
" Compared with intragastric administration, intranasal administration resulted in a shorter tmax (0."( Pharmacokinetics and efficiency of brain targeting of ginsenosides Rg1 and Rb1 given as Nao-Qing microemulsion.
Chen, G; Cheng, JY; Dian, SN; Huang, SL; Li, T; Liang, RC; Lv, XX; Shu, YJ; Yang, F; Yang, MQ, 2015
)
0.42
" It is valuable to investigate their pharmacokinetic and pharmacodynamic behavior and potential synergistic effect for better drug development and clinical application."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.62
"Pharmacokinetic and nitric oxide (NO) release pharmacodynamic drug-drug interactions of ginsenoside Rg1, ginsenoside Rb1 and schisandrin were studied after intravenous administration of each compound with the dose of 10 mg/kg and their mixture with the total dose of 10 mg/kg to isoproterenol (ISO)-induced myocardial ischemia rats."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.84
"The result obtained from this study suggested pharmacokinetic and pharmacodynamic drug-drug interactions between ginsenoside Rg1, Rb1 and schisandrin."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.62
" Pharmacokinetic parameters were estimated using non-compartmental methods."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
" The values of Cmax and AUC(0-t) after IT were significantly higher than IV."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
" Co-administration of Danshen and Sanqi could cause significant pharmacokinetic herb-herb interactions in guinea pigs."( In vivo distribution and pharmacokinetics of multiple active components from Danshen and Sanqi and their combination via inner ear administration.
Chen, G; Long, W; Mu, L; Wen, L; Yang, F; Zhang, SC, 2014
)
0.4
" Our findings demonstrated that consumption of lincomycin could lead to the formation of specific metabolites and pharmacokinetic changes of ginsenoside Rb1 in the gut, attributed to alterations in metabolic activities of intestinal bacteria."( Effects of broad-spectrum antibiotics on the metabolism and pharmacokinetics of ginsenoside Rb1: a study on rats׳ gut microflora influenced by lincomycin.
Fan, L; Li, X; Peng, Y; Wang, M; Xu, R, 2014
)
0.83
" In conclusion, the dys-regulated fecal β-d-glucosidase activity and deglycosylation metabolism may contribute to the altered pharmacokinetic of ginsenoside Rb1 and its hydrolysis metabolites after ATMs treatment or restraint stress exposure."( Gut microbiota in the pharmacokinetics and colonic deglycosylation metabolism of ginsenoside Rb1 in rats: Contrary effects of antimicrobials treatment and restraint stress.
Di, L; Dong, Y; Kang, A; Shan, J; Wen, H; Xie, T; Zhang, S; Zhu, D, 2016
)
0.86
" The pharmacokinetic studies of FXT and PN were performed using the established method with the pharmacokinetic parameters being determined by non-compartmental analysis."( Effect of compatible herbs on the pharmacokinetics of effective components of Panax notoginseng in Fufang Xueshuantong Capsule.
Huang, JM; Li, MY; Ma, CH; Pang, HH; Tang, MK; Wang, Y,
)
0.13
" The analytical method was successfully applied to a pharmacokinetic study of the multi-components after oral administration of Sanjie Zhentong Capsule in rats."( Simultaneous determination of ten bioactive constituents of Sanjie Zhentong Capsule in rat plasma by ultra-high-performance liquid chromatography tandem mass spectrometry and its application to a pharmacokinetic study.
Hu, JH; Huang, W; Li, D; Li, J; Pan, Y; Wang, Y; Wang, ZZ; Xiao, W, 2017
)
0.46
"LC-MS/MS method was established to analyze five ingredients, notoginsenoside R1 (R1), ginsenoside Rg1 (Rg1), ginsenoside Rb1 (Rb1), ginsenoside Re (Re), and ginsenoside Rd (Rd), in rats' plasma to describe the pharmacokinetic parameters of PNS."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.69
"The pharmacokinetic parameters were significantly different after oral administration three formulations."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
" To investigate the pharmacokinetic interaction between FDDP and CBT after oral administration of FDDP, CBT and their combination in rats, a novel LC-MS method with segmented scan modes (multiple reaction monitoring and selected ion monitoring) and polarity (positive and negative ionization) was developed."( Segmented scan modes and polarity-based LC-MS for pharmacokinetic interaction study between Fufang Danshen Dripping Pill and Clopidogrel Bisulfate Tablet.
Du, Y; Guo, MZ; Ji, L; Ji, S; Ma, YS; Shao, X; Su, ZY; Tang, DQ; Wang, YJ; Zhao, L, 2019
)
0.51
" In view of its undefined applicable population and dosage, a population pharmacokinetic (PPK) study is required."( UFLC-MS/MS Determination and Population Pharmacokinetic Study of Tanshinol, Ginsenoside Rb1 and Rg1 in Rat Plasma After Oral Administration of Compound Danshen Dripping Pills.
Chu, Y; Jin, T; Li, S; Liu, Z; Ma, X; Sun, H; Wang, G; Wang, X; Yang, J; Zhou, S, 2020
)
0.79
"As a preliminary exploration toward the clinical population pharmacokinetic research, this study provides a reference for the population pharmacokinetic study of traditional CMM."( UFLC-MS/MS Determination and Population Pharmacokinetic Study of Tanshinol, Ginsenoside Rb1 and Rg1 in Rat Plasma After Oral Administration of Compound Danshen Dripping Pills.
Chu, Y; Jin, T; Li, S; Liu, Z; Ma, X; Sun, H; Wang, G; Wang, X; Yang, J; Zhou, S, 2020
)
0.79
" However, the pharmacokinetic characteristics of its major bioactive components under pathological conditions are unclear."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91
"This method was successfully applied to the pharmacokinetic investigation of seven major components of C-QSP and P-QSP following oral administration in CHF model rats."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91
"The pharmacokinetic parameters of bioactive components were significantly changed for better bioavailability and absorption, longer lasting time elimination, which were beneficial for enhancing therapeutic efficacy in the P-QSP group."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91
" LC-MS/MS technique was employed to investigate the pharmacokinetic characteristics of GRb1 and GRb1@PLGA@NPs in rat plasma."( Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles.
Du, L; Guo, Z; Li, Y; Lu, H; Xiao, Y, 2023
)
1.15

Compound-Compound Interactions

ExcerptReferenceRelevance
"Pharmacokinetic and nitric oxide (NO) release pharmacodynamic drug-drug interactions of ginsenoside Rg1, ginsenoside Rb1 and schisandrin were studied after intravenous administration of each compound with the dose of 10 mg/kg and their mixture with the total dose of 10 mg/kg to isoproterenol (ISO)-induced myocardial ischemia rats."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.84
"The result obtained from this study suggested pharmacokinetic and pharmacodynamic drug-drug interactions between ginsenoside Rg1, Rb1 and schisandrin."( A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S, 2014
)
0.62
" Therefore, when combined with HSA, the transformations of four ginsenosides still exhibit similar, although in different binding cavities in subdomain IIA and IIIA by making the methyls at C26 and C27 perpendicular plugging into the hydrophobic site of HSA, while the aglycone and glucose nearby are perpendicularly exposed outside to fit other suitable active targeting sites."( Based on SERS conformational studies of ginsenoside Rb1 and its metabolites before and after combined with human serum albumin.
Bai, X; Wang, Y; Zhang, W; Zhao, B, 2015
)
0.68
" A microdialysis combined with UPLC-MS/MS method was first established to compare the pharmacokinetics of seven major bioactive components in CHF model rats after oral administration of C-QSP and P-QSP."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91

Bioavailability

Ginsenoside Rb1 (GsRb1) is the best constituent of ginseng. It shows clinical efficacy as an antineoplastic, antioxidative and antirheumatic agent. Its oral bioavailability is poor due to its limited solubility.

ExcerptReferenceRelevance
" The elimination in stomach, large intestine and liver contributed to the low bioavailability of PNS, but the low membrane permeability might be a more important factor dominating the extent of absorption."( [Mechanism of oral absorption of panaxnotoginseng saponins].
Bai, ZH; Fang, XL; Han, LM; Han, M; Wang, QS, 2006
)
0.33
" Meanwhile, linearity correlation between Pe and ratio of relative bioavailability (Fr) was acquired for undiluted microemulison (ME)."( [Screening of Panax notoginsenoside water in oil microemulsion formulations and their evaluation in vitro and in vivo].
Fang, XL; Fu, S; Han, M, 2007
)
0.34
" Therefore, poor intestinal absorption is a primary reason for the low bioavailability of both Rg1 and Rb1."( [Comparison between the characteristics of absorption and pharmacokinetic behavior of ginsenoside Rg1 and ginsenoside Rb, of Panax notoginseng saponins].
Fang, XL; Fu, S; Han, M, 2007
)
0.34
"PNS-Phospholipid complex and a lipid-based formulation by dissolving the complex in the medium chain fattyglycerides were prepared, and their oral relative bioavailability was determined in rats and compared with an aqueous solution of PNS for each component."( The use of lipid-based formulations to increase the oral bioavailability of Panax notoginseng saponins following a single oral gavage to rats.
Guo, J; Huang, L; Meng, B; Ping, Q; Xiong, J, 2008
)
0.35
" The experimental result in rats in vivo showed that the oral relative bioavailability was enhanced remarkably by these lipid-based formulations composed of the PNS-Phospholipid complex and various esters."( The use of lipid-based formulations to increase the oral bioavailability of Panax notoginseng saponins following a single oral gavage to rats.
Guo, J; Huang, L; Meng, B; Ping, Q; Xiong, J, 2008
)
0.35
"The oral relative bioavailability of ginsenoside Rg1 and Rb1 of PNS was enhanced remarkably by the lipid-based formulations."( The use of lipid-based formulations to increase the oral bioavailability of Panax notoginseng saponins following a single oral gavage to rats.
Guo, J; Huang, L; Meng, B; Ping, Q; Xiong, J, 2008
)
0.35
" Meanwhile, ginsenoside Rb1 is the P-gp substrate, and could increase its fraction of bioavailability by corporation with P-gp inhibitor."( [Studies on influence factors of gnsenoside Rg1 and Rb1 absorption in intestines of rats].
Ji, Y; Li, W; Nan, L; Sun, X; Sun, Z, 2009
)
0.73
" However, its bioavailability is low after oral administration due to poor absorption."( Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats.
Chen, Z; Jiang, Y; Liu, X; Lu, T; Ma, M; Wei, N; Xu, G; Yue, X; Zhou, Z, 2011
)
0.76
"Diabetes mellitus is associated with decreased NO bioavailability in the myocardium."( Ginsenoside Rb1 preconditioning enhances eNOS expression and attenuates myocardial ischemia/reperfusion injury in diabetic rats.
Hou, JB; Wu, Y; Xia, R; Xia, ZY; Xu, JJ; Zhang, L; Zhao, B, 2011
)
1.81
" All three ginsenosides had poor oral bioavailability (0."( Determination of ginsenosides Rb1, Rb2, and Rb3 in rat plasma by a rapid and sensitive liquid chromatography tandem mass spectrometry method: Application in a pharmacokinetic study.
Liu, M; Liu, Z; Su, C; Su, W; Tang, L; Yang, C; Zhao, J, 2012
)
0.38
" As the main active constituents of Panax ginseng, ginsenosides are well known, poorly absorbed chemicals."( Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 in the Intestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats after Oral Administration.
Chen, Y; Guo, H; Hu, M; Li, F; Li, J; Li, Y; Liu, C; Liu, L; Liu, X; Xu, P; Zhang, J; Zhang, M; Zhong, Z, 2015
)
0.64
"After ingestion of ginseng, the bioavailability of its parent compounds is low and enteric microbiota plays an important role in parent compound biotransformation to their metabolites."( Significant difference in active metabolite levels of ginseng in humans consuming Asian or Western diet: The link with enteric microbiota.
Bissonnette, M; Chang, EB; Li, P; Liu, Z; Musch, MW; Qi, LW; Wan, JY; Wang, CZ; Yuan, CS; Zhang, QH, 2017
)
0.46
" The application is restricted by low bioavailability partly due to Panax notoginseng saponins (PNS) instability and low in vivo absorption."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
"It was found that the modification with adhesive materials improved PNS bioavailability in Fufang Danshen formula."( Pharmacokinetics of Panax notoginseng Saponins in Adhesive and Normal Preparation of Fufang Danshen.
Bai, J; Chen, XN; Du, SY; Li, DQ; Li, PY; Lu, Y; Tian, ZH; Wu, YL; Yu, GY; Zeng, YY; Zhao, MD, 2018
)
0.48
"Rb1 micelle formulations have great potential as a novel ocular drug delivery system to improve the bioavailability of drugs such as diclofenac."( Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery.
Lan, J; Li, M; Li, X; Lu, X; Wang, H; Wu, X; Xin, M; Zhang, F; Zhuang, Z, 2019
)
0.79
"Ginsenoside Rb1 (GsRb1) is the best constituent of ginseng and although it shows clinical efficacy as an antineoplastic, antioxidative and antirheumatic agent, its oral bioavailability is poor due to its limited solubility."( Anti-inflammatory and anti-gouty-arthritic effect of free Ginsenoside Rb1 and nano Ginsenoside Rb1 against MSU induced gouty arthritis in experimental animals.
Liu, Y; Ye, Q; Zhou, W; Zhu, H, 2020
)
2.25
" It suggested that the potential interactions of SMS with CYP 3A drug substrates should be noticed, especially the drugs whose bioavailability depends heavily on intestinal CYP3A."( Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats.
Chia-Hui Tan, E; Chiang, TY; Lee, IJ; Ueng, YF; Wang, HJ; Wang, YC; Yun, CH, 2021
)
0.62
"The pharmacokinetic parameters of bioactive components were significantly changed for better bioavailability and absorption, longer lasting time elimination, which were beneficial for enhancing therapeutic efficacy in the P-QSP group."( Comparative pharmacokinetics of seven bioactive components after oral administration of crude and processed Qixue Shuangbu Prescription in chronic heart failure rats by microdialysis combined with UPLC-MS/MS.
Chen, L; Chen, Y; Jiang, Y; Kong, M; Li, J; Wang, Q; Wei, N; Xu, L; Yuan, C, 2023
)
0.91
" GRb1@PLGA@NPs formulated using the optimal process exhibited uniform distribution and stable quality, its relative oral bioavailability was significantly improved compared to free GRb1."( Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles.
Du, L; Guo, Z; Li, Y; Lu, H; Xiao, Y, 2023
)
1.15

Dosage Studied

Mice were injected with ginsenoside Rb1 and rosiglitazone with the dosage of 20 mg x kg(-1) and 10 mg xkg(-1), respectively. Study found significant decrement of scar elevation index, in comparison with control and lower dosage groups.

ExcerptRelevanceReference
" GRb1 at these dosage significantly increased the amount of mucus secretion in an ethanol-induced model."( Ginsenoside Rb1: the anti-ulcer constituent from the head of Panax ginseng.
Hyun, JE; Jeong, CS; Kim, YS, 2003
)
1.76
" Mice in Rb1 group and Rog groups were intraperitoneally injected with ginsenoside Rb1 and rosiglitazone with the dosage of 20 mg x kg(-1) and 10 mg x kg(-1), respectively."( [Effect of ginsenoside Rb1 in ameliorating insulin resistance and ectopic fat deposition in obese mice induced by high fat diet].
Shang, WB; Wang, GQ; Yu, XZ; Zhao, J, 2013
)
1.01
"56mg of ginsenoside Rb1 resulted in significant decrement of scar elevation index, in comparison with control and lower dosage groups, furthermore achieved broader and randomly arranged collagen fibers resembling findings in normal dermis."( Effects of ginsenoside Rb1 on hypertrophic scar remodeling in rabbit model.
Kang, EH; Lee, DW; Lee, MC; Lew, DH; Roh, H; Tark, KC, 2015
)
1.24
" Male rats were divided into ten groups: blank group (B-Group), model group (D-Group), Rb1 group (Rb1-Group), CK group (CK-Group), GP groups and GP + Rb1 groups in dosage of high, middle and low (H-Group, M-Group, L-Group, H-Rb1-Group, M-Rb1-Group, and L-Rb1-Group)."( Mechanism of antidiabetic and synergistic effects of ginseng polysaccharide and ginsenoside Rb1 on diabetic rat model.
Dai, Y; Ge, Y; Li, J; Li, N; Li, R; Yu, S; Yue, H; Zheng, F, 2018
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
anti-obesity agentAny substance which is used to reduce or control weight.
anti-inflammatory drugA substance that reduces or suppresses inflammation.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
ginsenosideTriterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.
glycosideA glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively.
tetracyclic triterpenoidAny triterpenoid consisting of a tetracyclic skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
ginsenosides biosynthesis225
ginsenoside degradation I06
ginsenoside degradation II05
ginsenosides biosynthesis1032

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)250.00000.02101.862610.0000AID480992
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)250.00000.48004.35649.9400AID480993
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)250.00000.00030.71237.0700AID480992
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)EC50 (µMol)0.01680.01681.24885.9000AID1364697
5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)EC50 (µMol)0.01680.01681.34635.9000AID1364697
5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)EC50 (µMol)0.01680.01681.24885.9000AID1364697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (66)

Processvia Protein(s)Taxonomy
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of glycolytic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
spermatogenesis5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
positive regulation of protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
import into nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
regulation of catalytic activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
lipid droplet disassembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
chromatin remodeling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cholesterol biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
lipid biosynthetic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of autophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of gene expression5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
response to muscle activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Wnt signaling pathway5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of macroautophagy5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TOR signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to oxidative stress5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose starvation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
glucose homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of circadian rhythm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of glycolytic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
rhythmic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
fatty acid homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of stress granule assembly5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
regulation of microtubule cytoskeleton organization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to calcium ion5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to glucose stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to prostaglandin E stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cellular response to xenobiotic stimulus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
energy homeostasis5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of protein localization5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of hepatocyte apoptotic process5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of TORC1 signaling5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
negative regulation of tubulin deacetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein localization to lipid droplet5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
positive regulation of peptidyl-lysine acetylation5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein phosphorylation5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
fatty acid biosynthetic process5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
positive regulation of gene expression5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
cellular response to nutrient levels5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
nail development5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
positive regulation of cold-induced thermogenesis5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
signal transduction5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cAMP-dependent protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
AMP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase regulator activity5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
ADP binding5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
chromatin binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
AMP-activated protein kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
ATP binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
metal ion binding5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein serine kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
histone H2BS36 kinase activity5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
protein kinase activity5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
protein binding5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
protein kinase binding5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
membrane5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
Golgi apparatus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytosol5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasmic stress granule5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nuclear speck5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
axon5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
dendrite5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
neuronal cell body5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase catalytic subunit alpha-2Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
nucleoplasm5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
cytosol5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
nucleotide-activated protein kinase complex5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
nucleus5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
cytoplasm5'-AMP-activated protein kinase subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID359490Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID397122Inhibition of HIV1 RT
AID359487Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1210051Cytoprotective activity in neonatal HDF assessed as reduction of BaP-induced DNA strand breakage by measuring tunnel positive cells at 10 uM after 24 hrs (Rvb = 15.96%)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage.
AID480997Cytotoxicity against human PC3 cells at 25 uM after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID359489Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID480995Cytotoxicity against human A549 cells at 25 uM after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID1611954Cytotoxicity against mouse B16 cells assessed as cell viability at 1000 uM after 48 hrs by MTT assay relative to control2018Journal of medicinal chemistry, 09-13, Volume: 61, Issue:17
Inhibitors of Melanogenesis: An Updated Review.
AID1210050Cytotoxicity against neonatal HDF assessed as cell viability at 10 uM after 24 hrs by MTT assay relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage.
AID359682Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1172640Inhibition of cell proliferation of rat C6 cells assessed as cell viability at 100 uM after 72 hrs by sulforhodamine B assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Bioactive triterpenoid saponins and phenolic compounds against glioma cells.
AID397814Induction of neurite outgrowth in human SK-N-SH cells at 100 uM after 5 days relative to control2002Journal of natural products, Sep, Volume: 65, Issue:9
Dammarane-type Saponins from Panax japonicus and their neurite outgrowth activity in SK-N-SH cells.
AID481001Cytotoxicity against human PANC1 cells at 25 uM after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID337107Hepatoprotective activity against D-galactosamine/LPS-induced liver injury in ddY mouse assessed as inhibition of serum alanine transaminase level at 100 mg/kg, ip administered 1 hr before D-galactosamine/LPS challenge by Reitman-Frankel method2003Journal of natural products, Jul, Volume: 66, Issue:7
Structures of new dammarane-type Triterpene Saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal Ginseng Saponins.
AID1364697Activation of recombinant AMPKalpha2beta1gamma1 (unknown origin) expressed in Escherichia coli BL21 in presence of CaMKKbeta (unknown origin) incubated for 45 mins in presence of substrate-1 peptide and ATP by HTRF assay2017Journal of natural products, 04-28, Volume: 80, Issue:4
Malonylginsenosides with Potential Antidiabetic Activities from the Flower Buds of Panax ginseng.
AID359495Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID595752Cytotoxicity against human DU145 cells assessed as growth inhibition after 3 days by sulforhodamine B assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID480992Inhibition of human DNA topoisomerase 1-mediated relaxation of supercoiled DNA by gel electrophoresis2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID1172639Inhibition of cell proliferation of human U251 cells assessed as cell viability at 100 uM after 72 hrs by sulforhodamine B assay2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Bioactive triterpenoid saponins and phenolic compounds against glioma cells.
AID359683Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1256912Inhibition of human IDH1 R132H mutant expressed in IPTG-induced Escherichia coli BL21 cells assessed as oxidation of NADPH to NADP+ after 5 mins by spectrophotometry2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
AID480999Cytotoxicity against human HL60 cells at 25 uM after 48 hrs by WST8 assay2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID595749Inhibition of fMLP/CB-stimulated superoxide anion generation in human neutrophils at 30 uM relative to control2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID359494Hepatoprotective activity against D-galactosamine/TNFalpha-induced cell death in mouse hepatocytes assessed cell survival rate at 100 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs by MTT assay2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID1210052Cytoprotective activity in neonatal HDF assessed as reduction of BaP-induced tail moment at 10 uM after 24 hrs by comet assay2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage.
AID359493Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death at 50 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID334335Induction of morphological transformation of rat ASK cells into astrocytes at 100 ug/ml after 1 hr by light microscopy
AID362265Antioxidant activity assessed as inhibition of hydroxyl radical production at 0.5% concentration%2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
The chemical and hydroxyl radical scavenging activity changes of ginsenoside-Rb1 by heat processing.
AID595750Inhibition of fMLP/CB-activated human neutrophil degranulation assessed as inhibition of elastase release at 30 uM using MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide as a substrate after 5 mins relative to control2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID362267Antioxidant activity assessed as inhibition of hydroxyl radical production at 0.05% concentration%2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
The chemical and hydroxyl radical scavenging activity changes of ginsenoside-Rb1 by heat processing.
AID671762Inhibition of HCV NS3 helicase overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of DNA unwinding activity at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID480993Inhibition of human DNA topoisomerase 2-mediated relaxation of supercoiled DNA by gel electrophoresis2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Cytotoxicity and inhibition of DNA topoisomerase I of polyhydroxylated triterpenoids and triterpenoid glycosides.
AID595751Cytotoxicity against human KB cells assessed as growth inhibition after 3 days by sulforhodamine B assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID1256913Inhibition of human IDH1 expressed in IPTG-induced Escherichia coli BL21 cells assessed as reduction of NADP+ to NADPH after 5 mins by spectrophotometry2015Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23
Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
AID1210049Cytoprotective activity in neonatal HDF assessed as reduction of BaP-induced cell death at 10 uM after 24 hrs by MTT assay2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Cytoprotective effect of 20S-Rg3 on benzo[a]pyrene-induced DNA damage.
AID671761Inhibition of SARS coronavirus nsP13 helicase activity expressed in Escherichia coli Rosetta assessed inhibition of DNA unwinding activity at 10 uM by FRET assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID671764Inhibition of HCV NS3 helicase ATP hydrolysis activity overexpressed in Escherichia coli BL21(DE3) assessed as inhibition of inorganic phosphate release by AM/MG-based colometric analysis in the presence of M13 ssDNA2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.
AID595753Cytotoxicity against human A549 cells assessed as growth inhibition after 3 days by sulforhodamine B assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID362266Antioxidant activity assessed as inhibition of hydroxyl radical production after heat processing2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
The chemical and hydroxyl radical scavenging activity changes of ginsenoside-Rb1 by heat processing.
AID397817Effect on neurite outgrowth activity in human SK-N-SH cells assessed as increase in number of vericosites at 100 uM after 5 days2002Journal of natural products, Sep, Volume: 65, Issue:9
Dammarane-type Saponins from Panax japonicus and their neurite outgrowth activity in SK-N-SH cells.
AID359484Hepatoprotective activity in mouse hepatocytes assessed protection against D-galactosamine/TNFalpha-induced cell death at 200 uM administered before 30 mins of TNFalpha challenge measured after 18 hrs2001Journal of natural products, Apr, Volume: 64, Issue:4
Triterpene saponins from Vietnamese ginseng (Panax vietnamensis) and their hepatocytoprotective activity.
AID337110Hepatoprotective activity against D-galactosamine/LPS-induced liver injury in ddY mouse assessed as inhibition of serum aspartate transaminase level at 100 mg/kg, ip administered 1 hr before D-galactosamine/LPS challenge by Reitman-Frankel method2003Journal of natural products, Jul, Volume: 66, Issue:7
Structures of new dammarane-type Triterpene Saponins from the flower buds of Panax notoginseng and hepatoprotective effects of principal Ginseng Saponins.
AID595754Cytotoxicity against human HCT8 cells assessed as growth inhibition after 3 days by sulforhodamine B assay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Bioactive constituents from the roots of Panax japonicus var. major and development of a LC-MS/MS method for distinguishing between natural and artifactual compounds.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (557)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (0.36)18.2507
2000's150 (26.93)29.6817
2010's310 (55.66)24.3611
2020's95 (17.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.04 (24.57)
Research Supply Index6.35 (2.92)
Research Growth Index6.89 (4.65)
Search Engine Demand Index60.75 (26.88)
Search Engine Supply Index2.91 (0.95)

This Compound (33.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.53%)5.53%
Reviews14 (2.46%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other551 (97.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]